[144] Block, Inc. SEC Filing

Rhea-AI Filing Summary

Schedule 13G filing – Blueprint Medicines Corp. (BPMC)

Hedge-fund complex Davidson Kempner and affiliates (M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP and managing member Anthony A. Yoseloff) disclose beneficial ownership of 0 shares and 0% of BPMC common stock as of the 14 Jul 2025 reportable event. Rows 5-8 of each cover page show no sole or shared voting or dispositive power. Item 5 confirms they now hold “5 percent or less” of the class. Historically, the group previously exceeded the 5 % threshold, triggering the original 13G; this amendment reflects a complete exit or reduction below the reporting threshold.

All reporting persons list the same business address (9 W 57th St., New York) and certify the shares were not acquired to influence control. The filing therefore signals that a significant institutional holder has fully unwound its position in Blueprint Medicines.

Positive

• None.

Negative

• Large institutional holder has reduced its position in BPMC to 0 %, eliminating prior >5 % stake

Insights

Portfolio Manager

TL;DR: Davidson Kempner reports 0% stake in BPMC, indicating full exit by a once-large holder.

The filing shows all affiliated entities now control no shares. Hedge-fund departures can signal profit-taking or diminished conviction. While not dilutive, it removes a potential “sticky” shareholder that might have supported the stock during volatility. Absence of voting power also reduces activist risk from this group. Investors should monitor trading volumes around 14 Jul 2025 to gauge if the exit pressured share price.

Corporate Governance Specialist

TL;DR: Governance impact minimal; disclosure formalises sub-5 % status.

Because the group certifies no intent to influence control, governance ramifications are limited. The exit diminishes concentration among top holders, potentially broadening the float. Management loses a knowledgeable biotech investor but gains marginally more flexibility in strategic actions without needing to consult this fund.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	16358	1285738.80	615019000	07/21/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/01/2023	Restricted Stock	ISSUER			5019	01/01/2023	Not Applicable
Common	07/01/2025	Restricted Stock	ISSUER			1276	07/01/2025	Not Applicable
Common	05/20/2025	Restricted Stock	ISSUER			6275	05/20/2025	Not Applicable
Common	11/01/2022	Restricted Stock	ISSUER			3788	11/01/2022	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AMRITA AHUJA 1955 Broadway, Suite 600 Oakland CA 95612	Common	07/02/2025	1351	93570.67
AMRITA AHUJA 1955 Broadway, Suite 600 Oakland CA 95612	Common	05/21/2025	10002	564009.58

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Why did Davidson Kempner file a Schedule 13G for Blueprint Medicines (BPMC)?

Because its aggregate holdings dropped to 5 % or less, requiring an update under SEC Rule 13d-1.

How many Blueprint Medicines shares does Davidson Kempner currently own?

The filing lists 0 shares with no voting or dispositive power.

What percentage of BPMC’s outstanding shares does this represent?

The reported ownership is 0 % of the common stock class.

Does the filing indicate an attempt to influence Blueprint Medicines’ control?

No. The certification states the securities were not acquired to change or influence control.

When was the reportable event triggering this filing?

The event date is 14 July 2025, with signatures dated 21 July 2025.